These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11712625)

  • 41. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
    Carey PD; Warwick J; Niehaus DJ; van der Linden G; van Heerden BB; Harvey BH; Seedat S; Stein DJ
    BMC Psychiatry; 2004 Oct; 4():30. PubMed ID: 15482603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder.
    Grant JE; Mancebo MC; Weinhandl E; Odlaug BL; Eisen JL; Rasmussen SA
    Int Clin Psychopharmacol; 2013 Jul; 28(4):200-5. PubMed ID: 23587985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
    Stein DJ; Mendelsohn I; Potocnik F; Van Kradenberg J; Wessels C
    Depress Anxiety; 1998; 8(1):39-42. PubMed ID: 9750979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Tükel R; Bozkurt O; Polat A; Genç A; Atli H
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
    BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Miguel EC; Versiani M
    World J Biol Psychiatry; 2005; 6(1):57-9. PubMed ID: 16097406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making.
    da Conceição Costa DL; Shavitt RG; Castro Cesar RC; Joaquim MA; Borcato S; Valério C; Miguel EC; Diniz JB
    J Psychiatr Res; 2013 Nov; 47(11):1700-7. PubMed ID: 23948637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcome in adults with obsessive-compulsive disorder.
    Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
    Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
    Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
    CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.